顔面肩甲上腕型筋ジストロフィー 1 型成人患者における ARO-DUX4 の研究
顔面肩甲上腕型筋ジストロフィー 1 型成人患者における ARO-DUX4 の安全性、忍容性、薬物動態、および薬力学を評価するための第 1/2a 相用量漸増研究
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRP-1001 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of SRP-1001 or placebo. In Part 2 of the study, participants will receive 4 doses of SRP-1001 or placebo. Participants who complete Part 1 will have the option to re-screen and re-randomize into Part 2. All participants will undergo pre- and post-dose magnetic imaging resonance (MRI)-guided muscle biopsies (a total of 2 biopsies). Participants who complete Part 1 and enroll in Part 2 will be required to undergo an additional screening biopsy. Participants completing Part 1 or Part 2 may have the option to continue to receive drug in an open-label extension study or may be eligible to participate in later-stage clinical studies.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Milan、イタリア、20162
- Centro Clinico Nemo Milann
-
Roma、イタリア、00168
- Fondazione Policlinico Universitario A. Gemelli
-
-
-
-
-
Leiden、オランダ、2333
- Centre For Human Drug Research
-
-
-
-
New South Wales
-
Liverpool、New South Wales、オーストラリア、2170
- Liverpool Hospital
-
-
Queensland
-
Auchenflower、Queensland、オーストラリア、4066
- Wesley Research Institute
-
Birtinya、Queensland、オーストラリア、4575
- Sunshine Coast University Hospital
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3004
- Alfred Health
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N4Z6
- University of Calgary
-
Edmonton、Alberta、カナダ、T6G2G4
- University of Alberta
-
-
Quebec
-
Montreal、Quebec、カナダ、H3A2B4
- McGill University
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Universitario Vall d'Hebron
-
Madrid、スペイン、28034
- Hospital Universitario Ramon y Cajal
-
Valencia、スペイン、46026
- Hospital Universitari l Politecnic La Fe de Valencia
-
-
-
-
-
München、ドイツ、80336
- Universitätsklinikum München
-
Ulm、ドイツ、89081
- Neurologische Universitätsklinik Am Rku
-
-
-
-
-
Auckland、ニュージーランド、1010
- New Zealand Clinical Research
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Genetically confirmed FSHD1 based on screening evaluation or source verifiable medical record
- Clinical severity score between 3 and 8 (scale, 0 to 10)
- Must have an eligible lower extremity muscle for biopsy as determined from MRI by a central reader, with muscle fat fraction ≥10% and less than approximately 40%
- Males or nonpregnant, nonlactating females ≥18 years of age who do not plan to become pregnant during the study, with an upper age limit of ≤70 years
- Able and willing to provide written informed consent prior to the performance of any study specific procedures
- Participants with a body mass index (BMI) between 18.0 and 35.0 kilograms/square meter, inclusive. A participant with FSHD1 and a BMI outside this range may be allowed into the study at the discretion of the principal investigator.
- Must have eligible lower extremity muscle for biopsy as determined from MRI by a central reader
- A 12-lead electrocardiogram at screening with no abnormalities that may compromise participant's safety in the study
- Participants of childbearing potential and their partners must use highly effective contraception during the study and for at least 9 months following the end of study or last dose of study medication, whichever is later. Males must not donate sperm during the study from Day 1 until at least 9 months following the end of study or last dose of study medication, whichever is later.
Key Exclusion Criteria:
- Human immunodeficiency virus (HIV) infection as shown by presence of anti-HIV antibody (seropositive) at screening
- Seropositive for hepatitis B or hepatitis C at screening
- Uncontrolled hypertension
- Severe cardiovascular disease
- History of thrombolic events
- Platelet count less that the lower limit of normal at screening
- History or presence of: a hypercoagulable state, nephrotic range proteinuria, antiphospholipid antibody syndrome, myeloproliferative disease, inability to ambulate, use of hormone-based contraceptives.
- Any contraindication to muscle biopsy or MRI
Note: additional inclusion/exclusion criteria may apply per protocol
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SRP-1001
SRP-1001 for injection |
Single or multiple doses of SRP-1001 by intravenous (IV) infusion
他の名前:
|
|
プラセボコンパレーター:Placebo
Sodium chloride (0.9%) |
Calculated volume to match active treatment by IV infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events Over Time Through End of Study
時間枠:Part 1: Up to Day 90; Part 2: Up to Day 360
|
Part 1: Up to Day 90; Part 2: Up to Day 360
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
PK of SRP-1001: Maximum Observed Plasma Concentration (Cmax)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Quantifiable Plasma Concentration (AUClast)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Area Under the Plasma Concentration Versus Time from Zero to Infinity (AUCinf)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Terminal Elimination Half-Life (t1/2)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Systemic Clearance (CL)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Volume of Distribution (Vss)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Recovery of Unchanged Drug in Urine Over 0-24 Hours (Amount Excreted: Ae)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Fraction of Drug Excreted in Urine as Percent of IV Dose (Fe)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
|
PK of SRP-1001: Renal Clearance (CLr)
時間枠:Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
Part 1: through 48 hours post-dose (all cohorts) and through 48 hours post second dose (Cohorts 3 & 4 only); Part 2: through 8 hours post first and second dose
|
協力者と研究者
捜査官
- スタディディレクター:Medical Director、Sarepta Therapeutics, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SRP-1001-101
- 2023-509748-89-00 (Ctis)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。